Theralase® Technology Effective in Virus Inactivation

TORONTO, ON / ACCESSWIRE / June 4, 2024 / Theralase® Technologies Inc., a clinical-stage pharmaceutical company, announced that its lead compound, Ruvidar™, has shown efficacy in the inactivation of various viruses. The research was conducted at the University of Manitoba and the National Microbiology Laboratory.

The study, recently published in Heliyon, demonstrated that Ruvidar™ is effective against both enveloped and non-enveloped viruses, with or without light activation. The compound also showed promise in treating human coronavirus, potentially acting as a vaccine.

Kevin Coombs, Ph.D., University of Manitoba, stated, "Ruvidar™ is far more potent than other antiviral compounds we've tested, effective at 100-fold lower concentrations. It has inactivated 90 to 99.9% of viruses like H1N1, coronavirus, Zika, poxvirus, and herpes virus."

Arkady Mandel, Chief Scientific Officer, expressed excitement about the publication's acceptance, noting plans to develop Ruvidar™ as a topical therapeutic for herpes virus lesions. CEO Roger DuMoulin-White mentioned plans to pivot research towards an avian influenza vaccine.